Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Avecho Biotechnology Limited ( (AU:AVE) ).
Avecho Biotechnology Limited held its Annual General Meeting where all proposed resolutions were carried, including the adoption of the remuneration report, re-election of Dr. Gregory Collier as a director, and approval of options grants to key personnel. The approval of a 10% placement facility was also secured, indicating strong shareholder support and potential for future capital raising, which could enhance the company’s financial flexibility and strategic initiatives.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is a company that develops and commercializes innovative human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). This system, derived from Vitamin E, enhances the solubility and absorption of drugs and nutrients. Avecho’s leading product is a cannabidiol (CBD) TPM soft-gel capsule, which is in Phase III clinical development for treating insomnia.
Current Market Cap: A$12.69M
Find detailed analytics on AVE stock on TipRanks’ Stock Analysis page.